CRBU Insider Trading
Insider Ownership Percentage: 9.50%
Insider Buying (Last 12 Months): $45,051.20
Insider Selling (Last 12 Months): $4,811.40
Caribou Biosciences Insider Trading History Chart
This chart shows the insider buying and selling history at Caribou Biosciences by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Caribou Biosciences Share Price & Price History
Current Price: $0.94
Price Change: ▲ Price Increase of +0.148 (18.73%)
As of 04/9/2025 03:44 PM ET
Caribou Biosciences Insider Trading History
Caribou Biosciences Institutional Trading History
Data available starting January 2016
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Read More on Caribou Biosciences
Volume
798,551 shs
Average Volume
1,579,031 shs
Market Capitalization
$87.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.36
Who are the company insiders with the largest holdings of Caribou Biosciences?
Who are the major institutional investors of Caribou Biosciences?
Which institutional investors are buying Caribou Biosciences stock?
During the last quarter, CRBU stock was acquired by institutional investors including:
- Green Alpha Advisors LLC
During the last year, these company insiders have bought Caribou Biosciences stock:
- Rachel E Haurwitz (CEO)
- Barbara G Mcclung (Insider)
Learn More investors buying Caribou Biosciences stock.